Geneious Biologics to Power Biological Drug Development

Geneious Biologics to Power Better Biological Drug Development

AUCKLAND, NZ – May 23, 2017 – Geneious Biologics, an enterprise software solution for screening antibodies and related constructs using sequence data, was launched today and will change the way scientists identify antibodies for use in biological drug development.

The Geneious Biologics software platform will allow biopharma and biotechnology enterprises to create highly annotated antibody databases, significantly improving their ability to leverage accumulated knowledge and gain insights into trends and relationships that may otherwise have been missed.

“Biopharmaceutical enterprises are generating huge volumes of data in the development of new antibody based therapeutics,” said Jannick Bendtsen, Vice President of Technology Services, Geneious Biologics.

“Geneious Biologics will help them combine and analyze data from different sources and find high-value candidate antibodies much faster than they’ve ever been able to before.”

An advanced application programming interface (API) enables Geneious Biologics to integrate with established data systems while a powerful filtering and query language allows scientists to quickly and accurately identify best performing antibodies, regardless of the data’s origin in their organization’s infrastructure.

“New technologies like Geneious Biologics will play an important role in allowing researchers to better leverage existing molecular data sets,” said Michael Skynner, Ph.D., Vice President of Operations at Bicycle Therapeutics.

“Working with Geneious Biologics to apply this application to the analysis of our unique data sets has been enabling for Bicycle Therapeutics and I can see how this could drastically improve speed and accuracy in other areas of drug development.”

"One of the remaining bottlenecks to efficiently identify optimal antibody candidates is antibody sequence processing. Providing insight into large antibody sequence and data sets, such as can be retrieved from Isogenica’s fully synthetic human Fab or llamdA VHH domain antibody libraries, will speed up biologic drug development,” said Guy Hermans, CSO of Isogenica Ltd.

“Geneious Biologics will allow our licensees to optimally use the data on the large number of leads retrieved from our libraries and, ultimately, enhance biologic drug development processes.”

Geneious Biologics was launched today at Bio-IT World in Boston. It is now generally available to enterprises engaged in commercial antibody discovery and screening. For more information about Geneious Biologics or to request a demonstration visit www.geneiousbiologics.com.

ends

© Scoop Media